158 related articles for article (PubMed ID: 25603690)
1. Role of isotretinoin in cancer prevention and management in malignancies associated with xeroderma pigmentosum.
Zaman S; Gillani JA; Nabeela ; Khattak R; Iqbal ; ul Ain N; Zanaib ; Fayyaz
J Ayub Med Coll Abbottabad; 2014; 26(2):255-7. PubMed ID: 25603690
[TBL] [Abstract][Full Text] [Related]
2. Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: case report.
Saade M; Debahy NE; Houjeily S
J Chemother; 1999 Aug; 11(4):313-7. PubMed ID: 10465136
[TBL] [Abstract][Full Text] [Related]
3. Isotretinoin for the treatment of squamous cell carcinoma arising on an epidermoid cyst.
Skroza N; Proietti I; Tolino E; Bernardini N; La Viola G; Nicolucci F; Pampena R; Mancini MT; Balduzzi V; Potenza C; Zuber S
Dermatol Ther; 2014; 27(2):94-6. PubMed ID: 24703265
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cancer in a child with ocular xeroderma pigmentosa (XP) in Malawi.
Schulze Schwering M; Chagaluka G; Molyneux E
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e540-2. PubMed ID: 24390455
[TBL] [Abstract][Full Text] [Related]
5. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum.
Hamouda B; Jamila Z; Najet R; Slim T; Rafiaa N; Noureddine B; Ahmed EM; Mohamed F; Ridha KM; Abderrahman L
J Am Acad Dermatol; 2001 Jun; 44(6):1054. PubMed ID: 11369927
[No Abstract] [Full Text] [Related]
6. [Topical and systemic chemotherapy with 5-fluouracil in facial carcinoma secondary to xeroderma pigmentosum].
Khader A; Gritli S; Boussen I; Oueslati Z; Ferjaoui M; Nouira R; Ladgham A; Boussen H
Tunis Med; 2005 Nov; 83(11):672-4. PubMed ID: 16422364
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of skin cancer in xeroderma pigmentosum.
Kraemer KH; DiGiovanna JJ; Peck GL
J Dermatol; 1992 Nov; 19(11):715-8. PubMed ID: 1293159
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic results of 5-fluorouracil in multiple and unresectable facial carcinoma secondary to xeroderma pigmentosum].
Boussen H; Zwik J; Mili-Boussen I; Rammeh N; Bouaouina N; Gritli S; el May A; Kammoun MR; Ouertani A; Ladgham A
Therapie; 2001; 56(6):751-4. PubMed ID: 11878102
[TBL] [Abstract][Full Text] [Related]
9. Cancer protection in xeroderma pigmentosum variant (XP-V).
Somos S; Farkas B; Schneider I
Anticancer Res; 1999; 19(3B):2195-9. PubMed ID: 10472330
[TBL] [Abstract][Full Text] [Related]
10. Xeroderma pigmentosum: spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy.
DiGiovanna JJ; Patronas N; Katz D; Abangan D; Kraemer KH
J Cutan Med Surg; 1998 Jan; 2(3):153-8. PubMed ID: 9479081
[TBL] [Abstract][Full Text] [Related]
11. Bilateral facial squamous cell carcinoma in an 18-month-old girl with xeroderma pigmentosum.
Alymlahi E; Dafiri R
J Postgrad Med; 2005; 51(2):128-30. PubMed ID: 16006708
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of 13-cis retinoic acid plus interferon-alpha in advanced squamous cell carcinoma of head and neck, refractory to chemotherapy.
Cascinu S; Del Ferro E; Ligi M; Graziano F; Castellani A; Catalano G
Ann Oncol; 1996 Jul; 7(5):538. PubMed ID: 8839916
[No Abstract] [Full Text] [Related]
13. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
14. Multiple facial basal cell carcinomas in xeroderma pigmentosum treated with topical imiquimod 5% cream.
Yang JQ; Chen XY; Engle MY; Wang JY
Dermatol Ther; 2015; 28(4):243-7. PubMed ID: 25754701
[TBL] [Abstract][Full Text] [Related]
15. The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin.
Giannotti B; Vanzi L; Difonzo EM; Pimpinelli N
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():33-5. PubMed ID: 14616811
[TBL] [Abstract][Full Text] [Related]
16. Dramatic response to nivolumab in xeroderma pigmentosum skin tumor.
Chambon F; Osdoit S; Bagny K; Moro A; Nguyen J; Réguerre Y
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28988442
[TBL] [Abstract][Full Text] [Related]
17. Bleomycin in xeroderma pigmentosum.
Short J; Price RA; Pratt CB
Cancer; 1973 Feb; 31(2):449-54. PubMed ID: 4120025
[No Abstract] [Full Text] [Related]
18. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up.
Seixas-Silva JA; Richards T; Khuri FR; Wieand HS; Kim E; Murphy B; Francisco M; Hong WK; Shin DM
Arch Otolaryngol Head Neck Surg; 2005 Apr; 131(4):304-7. PubMed ID: 15837897
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
[TBL] [Abstract][Full Text] [Related]
20. Prevention of skin cancer in xeroderma pigmentosum with oral isotretinoin.
Moshell AN
Cutis; 1989 May; 43(5):485-90. PubMed ID: 2721244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
